Get the Stockscreener App
30.04
1.04%
0.31
Roivant Sciences Ltd stock is traded at $30.04, with a volume of 5.30M.
It is up +1.04% in the last 24 hours and up +2.21% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$29.73
Open:
$30
24h Volume:
5.30M
Relative Volume:
0.95
Market Cap:
$21.61B
Revenue:
$8.26M
Net Income/Loss:
$-397.91M
P/E Ratio:
-59.65
EPS:
-0.5036
Net Cash Flow:
$-758.56M
1W Performance:
+5.11%
1M Performance:
+2.21%
6M Performance:
+35.93%
1Y Performance:
+161.90%
1-Day Range:
$29.87
$30.61
1-Week Range:
$28.29
$30.61
52-Week Range:
$10.71
$32.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
30.04 | 21.61B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Guggenheim and Citi Raise Roivant Sciences Price Targets After EarningsEarnings Surprise Score - newsline.com
Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - msn.com
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV) - Insider Monkey
ROIV: Brepocitinib leads a robust pipeline targeting rare diseases, with strong data and launch plans - TradingView
ROIV: Late-stage pipeline advances in rare diseases and immunology, with strong financial flexibility - TradingView
TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN
588,400 Shares in Roivant Sciences Ltd. $ROIV Purchased by ING Groep NV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with a 36.60% Potential Upside - DirectorsTalk Interviews
CenterBook Partners LP Purchases 364,390 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
10 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Goldman Sachs Group Inc. Buys 8,621,567 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences’ $2.25 Billion Moderna Settlement: Can Pipeline Momentum Follow? - Smartkarma
Precision Trading with Roivant Sciences Ltd. (ROIV) Risk Zones - Stock Traders Daily
WINTON GROUP Ltd Has $7.08 Million Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Norges Bank Makes New Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ROIV: Late-stage pipeline advances and imminent DM launch set up multiple catalysts for the year - TradingView
Legal & General Group Plc Has $12.80 Million Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
BNP Paribas Financial Markets Has $49.79 Million Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
ROIV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Did Roivant’s (ROIV) Profitable Quarter and $982 Million Shelf Filing Just Reframe Its Capital Strategy? - simplywall.st
Roivant Sciences Ltd. (ROIV) Stock Report: Analyzing The 30.18% Potential Upside - DirectorsTalk Interviews
Roivant shares climb on earnings beat despite revenue shortfall (ROIV) - MSN
Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum - simplywall.st
Roivant Sciences Ltd.Common Shares (NQ: ROIV - FinancialContent
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40 - Moomoo
ROIV Maintained by Guggenheim -- Price Target Raised to $36.00 - GuruFocus
Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing - Moomoo
Technical Reactions to ROIV Trends in Macro Strategies - Stock Traders Daily
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding - simplywall.st
TD Cowen Raises its Price Target on Roivant Sciences (ROIV) - Insider Monkey
Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV) - Yahoo Finance
Today's Analyst Rating | Roivant Sciences Price Target Raised to $31.5 by BofA Securities, UBS Downgrades Millicom International Cellular to Hold - Moomoo
Roivant Sciences Ltd. (ROIV) - DirectorsTalk Interviews
Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors? - Sahm
Roivant Sciences (ROIV) Slips Nearly 3% as Shares Test Key Support ZoneDealer Delta - thelegaladvocate.com
[Form 4] Roivant Sciences Ltd. Insider Trading Activity - Stock Titan
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $34 to $42 - Moomoo
ROIV Stock Price Prediction 2025-2026 | Roivant Sciences Ltd Forecast - 24/7 Wall St.
TD Cowen raises Roivant Sciences stock price target to $41 on trial data - Investing.com Australia
H.C. Wainwright reiterates Roivant Sciences stock rating on IMVT-1402 data By Investing.com - Investing.com South Africa
ROIV Maintained by Citigroup -- Price Target Raised to $42.00 - GuruFocus
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):